A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Inclusion Criteria:

* Colorectal cancer, locally recurrent, unresectable or metastatic disease (AJCC);
* Measurable disease (RECIST criteria);
* Cancer refractory to 5-FU/leucovorin or capecitabine, and irinotecan;
* ECOG performance score of 0-2;
* Adequate hematopoietic, liver and renal function;
* Adequate cardiac function (maximum of class II, NYHA);
* Women of child-bearing potential must have a negative urine or serum pregnancy test;
* Signed written informed consent;
* Subjects must be willing to to be followed during the course of treatment/observation and follow-up.

Exclusion Criteria:

* Other malignancies treated within the last five years, except in situ cervix carcinoma or non-melanoma skin cancer;
* Pregnant or breast feeding subjects, or male or female subjects of child producing potential who will not agree to use adequate contraception during the treatment phase of the study;
* Prior therapy with oxaliplatin;
* Known brain metastases;
* Active, uncontrolled infection or other serious medical illnesses;
* Subjects may not be using or have used any investigational therapy during four weeks before start of the protocol treatment.